A New Chapter in ESMO: Professor Yang Qingmo Analyzes Innovations in ADC Drug Therapy, Opening New Horizons for HR+ MBC Treatment
*For reference by medical professionals only ADC drugs reshape the stratified treatment strategy for HR+ advanced breast cancer In recent years, the rapid development of antibody-drug conjugates (ADC) has brought groundbreaking progress to the treatment of advanced breast cancer.Trastuzumab deruxtecan (T-DXd) and datopotamab deruxtecan (Dato-DXd) are representative drugs that are profoundly changing the treatment landscape … Read more